CLL-IBRU

Immune Signaling in Chronic Lymphocytic Leukemia and Ibrutinib response

Funding Body: Janssen Pharmaceuticals
Sponsorship, December 2014 – December 2016

In this project, in collaboration with the group by Dr. Paolo Ghia at the San Raffaele Scientific Institute in Milan, Italy, we will explore two major mechanisms that may underlie less than optimal responses to BcR inhibition by ibrutinib, namely: (i) “bypass” activation from non-BcR immune pathways, in particular the TLRs; and, (ii) resistance to signaling inhibitor-induced apoptosis in a context of BcR anergy associated with decreased dependence on proximal BcR signaling.

Contact

Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +302310498271